Brief Review of Compassionate Use of Remdesivir for Severe Covid-19— Grein 2020
This is a brief audio review. In the article Compassionate Use of Remdesivir for Patients with Severe Covid-19 published, 2020 by Grein and Colleagues, The outcomes and key points are as noted: This was a non randomized, non-controlled, prospective cohort study with a single arm. In severe COVID19, patients who recieved remdesivir tended to do better. 68% of patients improved in oxygen requirement statuses, 57% of patients on mechanical ventilation were extubated, 47% of patients were discharged, 13% of patients died, mortality for mechniacally ventilated patients was 18%, mortality was 5% among patients not recieving mechanical ventilation. This was a Prospective, cohort, (single arm), study with 53 patients who were patients with hospitalization for COVID19, confirmed diagnosis, with oxygen saturation of 94% or less on ambient air or who were recieving supplemental oxygen.
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, Nicastri E, Oda R, Yo K, Quiros-Roldan E, Studemeister A, Redinski J, Ahmed S, Bernett J, Chelliah D, Chen D, Chihara S, Cohen SH, Cunningham J, D'Arminio Monforte A, Ismail S, Kato H, Lapadula G, L'Her E, Maeno T, Majumder S, Massari M, Mora-Rillo M, Mutoh Y, Nguyen D, Verweij E, Zoufaly A, Osinusi AO, DeZure A, Zhao Y, Zhong L, Chokkalingam A, Elboudwarej E, Telep L, Timbs L, Henne I, Sellers S, Cao H, Tan SK, Winterbourne L, Desai P, Mera R, Gaggar A, Myers RP, Brainard DM, Childs R, Flanigan T. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020 Jun 11;382(24):2327-2336. doi: 10.1056/NEJMoa2007016. Epub 2020 Apr 10. PMID: 32275812; PMCID: PMC7169476.
